UVA radiation augments cytotoxic activity of psoralens in melanoma cells

Int J Radiat Biol. 2017 Jul;93(7):734-739. doi: 10.1080/09553002.2017.1297903. Epub 2017 Mar 13.

Abstract

Purpose: Melanoma is an aggressive form of skin cancer. The aim of the study was to evaluate the influence of UVA radiation and psoralens: 5-methoxypsoralen (5-MOP) or 8-methoxypsoralen (8-MOP) on melanoma cells viability.

Materials and methods: The amelanotic C32 and melanotic COLO829 human melanoma cell lines were exposed to increasing concentrations of psoralens (0.1-100 μM) in the presence or absence of UVA radiation. Cell viability was evaluated by the WST-1 assay.

Results: We demonstrated that 8-MOP, in contrast to 5-MOP, has no cytotoxic effect on both melanoma cell lines. Simultaneous exposure of cells to 8-MOP and UVA radiation caused significant cytotoxic response in C32 cells where the EC50 value was estimated to be 131.0 μM (UVA dose: 1.3 J/cm2) and 105.3 μM (UVA dose: 2.6 J/cm2). The cytotoxicity of 5-MOP on both C32 and COLO829 cells was significantly augmented by UVA radiation - the EC50 was estimated to be 22.7 or 7.9 μM (UVA dose: 1.3 J/cm2) and 24.2 or 7.0 μM (UVA dose: 2.6 J/cm2), respectively.

Conclusions: The demonstrated high cytotoxic response after simultaneous exposure of melanoma cells to psoralens and UVA radiation in vitro suggests the usefulness of PUVA therapy to treat melanoma in vivo.

Keywords: 5-methoxypsoralen; 8-methoxypsoralen; Melanoma; UVA radiation; cell viability.

MeSH terms

  • 5-Methoxypsoralen
  • Cell Line, Tumor
  • Cell Survival / drug effects*
  • Cell Survival / radiation effects*
  • Dose-Response Relationship, Drug
  • Dose-Response Relationship, Radiation
  • Drug Synergism
  • Humans
  • Melanoma / drug therapy*
  • Melanoma / pathology*
  • Methoxsalen / administration & dosage
  • Methoxsalen / analogs & derivatives
  • PUVA Therapy / methods*
  • Radiotherapy Dosage
  • Treatment Outcome

Substances

  • 5-Methoxypsoralen
  • Methoxsalen